Reuters logo
BRIEF-Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee in Japan
October 12, 2017 / 12:24 PM / 11 days ago

BRIEF-Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee in Japan

Oct 12 (Reuters) - Opko Health Inc

* Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee® in Japan

* Opko Health Inc - ‍Under terms of agreement, JT will make an upfront payment to Opko of $6 million

* Opko Health says unit ‍eirgen Pharma entered into an exclusive agreement with Japan Tobacco for development and commercialization in Japan of Rayaldee​

* Opko Health - As per agrement, co eligible to receive up to additional $31 million in development & regulatory milestones & $75 million in sales based milestones​

* Opko Health Inc - JT will make​ another ‍$6 million payment to co upon initiation of Opko’s planned phase 2 study of Rayaldee in U.S. dialysis patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below